

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**CanSino Biologics Inc.**  
**康希諾生物股份公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock code: 6185)**

**RESIGNATION OF DIRECTORS AND SUPERVISOR  
AND  
PROPOSED APPOINTMENT OF DIRECTORS AND SUPERVISOR**

**RESIGNATION OF DIRECTORS AND SUPERVISOR**

The board (the “**Board**”) of directors (the “**Directors**”) of CanSino Biologics Inc. (the “**Company**”) hereby announces that, (i) Dr. Luis BARRETO (“**Dr. Barreto**”) has tendered his resignation as an independent non-executive Director of the Company, a member of the remuneration and assessment committee under the Board (the “**Remuneration and Assessment Committee**”) and a member of the nomination committee under the Board (the “**Nomination Committee**”), with effect from the conclusion of the 2019 first extraordinary general meeting of the Company to be held on November 29, 2019 (the “**EGM**”), due to other work engagement; (ii) Dr. Pierre Armand MORGON (“**Dr. Morgon**”) has tendered his resignation as an independent non-executive Director of the Company, the chairman of the Remuneration and Assessment Committee and a member of the Nomination Committee, with effect from the conclusion of the EGM, due to other work engagement; and (iii) Mr. Jixiang ZHU (“**Mr. Zhu**”) has tendered his resignation as chairman of the board of supervisors (the “**Board of Supervisors**”) of the Company, with effect from the conclusion of the EGM, due to other work engagement.

The resigning Directors and supervisor have confirmed that they have no disagreement with the Company, the Board and the Board of Supervisors, and there are no other matters relating to their resignation that need to be brought to the attention of The Stock Exchange of Hong Kong Limited and the shareholders of the Company.

The Board would like to take this opportunity to thank Dr. Barreto, Dr. Morgon and Mr. Zhu for their valuable contributions to the Company.

**PROPOSED APPOINTMENT OF DIRECTORS AND SUPERVISOR**

In accordance with Article 72 of the articles of association of the Company, the Company Law of the People's Republic of China and applicable laws and regulations, Dr. Xuefeng YU, a controlling shareholder of the Company, nominates Mr. Shuifa GUI (桂水發) (“**Mr. Gui**”) and Mr. Jianzhong LIU (劉建忠) (“**Mr. Liu**”) as candidates for independent non-executive Directors of the first session of the Board, and nominates Ms. Jiangfeng LI (李江峰) (“**Ms. Li**”) as a candidate for supervisor of the first session of the Board of Supervisors. The Board agrees with the above mentioned proposal. The proposal will be submitted to the EGM for consideration and approval. The appointment of Mr. Gui and Mr. Liu as independent non-executive Directors and the appointment of Ms. Li as a supervisor will be effective upon the approval by the shareholders of the Company at the EGM.

The biographical details of Mr. Gui, Mr. Liu and Ms. Li are as follows.

**Mr. Shuifa GUI (桂水發)**, aged 54, has been serving as chief financial officer at Ucloud Technology Co., Ltd. (優刻得科技股份有限公司) since June 2018, and as director, chief financial officer and secretary of the board at Ucloud Technology Co., Ltd. since July 2018. Mr. Gui has been director of several companies, including executive director of Shanghai Shiniu Asset Management Co., Ltd. (上海師牛資產管理有限公司) since February 2013, director of Shanghai Tunnel Engineering Co., Ltd. (上海隧道工程股份有限公司) (a company listed on Shanghai Stock Exchange, stock code: 600820) since December 2018, independent non-executive director of Shanghai Mechanical & Electrical Industry Co., Ltd. (上海機電股份有限公司) (a company listed on Shanghai Stock exchange, stock code: 600835) since May 2018, director of Shanghai Zhengshi Intelligent Technology Co., Ltd. (上海證識智能科技有限公司) since June 2018, director of Wuhan Yintai Technology Power Co., Ltd. (武漢銀泰科技電源股份有限公司) since December 2014 and independent non-executive director of Linkage Software Co., Ltd. (蘇州工業園區凌志軟件股份有限公司) (a company listed on The National Equities Exchange And Quotations Co., Ltd., stock code: 830866) since April 2019.

Mr. Gui worked at Shanghai University of Finance and Economics (上海財經大學) and served as a teaching associate from July 1989 to December 1993. He served as business manager of Listing Department at Shanghai Stock Exchange from January 1994 to December 1997 and served as deputy director and director of Marketing Development Department from January 1998 to September 2001. From October 2001 to December 2011, he served as deputy general manager, chief financial officer and secretary of the board at Orient Securities Co., Ltd. (東方證券股份有限公司) (a company listed on Hong Kong Stock Exchange (stock code: 03958) and Shanghai Stock Exchange (stock code: 600958)). He served as chairman of the board at China Universal Asset Management Co., Ltd. (匯添富基金管理有限公司) from October 2004 to April 2012. From April 2012 to August 2017, he served as president at Landgent Group Co., Ltd. (樂成集團有限公司). From September 2017 to May 2018, he served as deputy general manager at E-Capital Transfer Co., Ltd. (證通股份有限公司).

Mr. Gui obtained his bachelor's degree in accounting from Shanghai University of Finance and Economics in June 1989. He received his master's degree in business management from the University of Hong Kong in September 2004. He has been a member of the Chinese Institute of Certified Public Accountants (中國註冊會計師協會) since April 1998.

**Mr. Jianzhong LIU (劉建忠)**, aged 55, has been serving as vice president at Yingu Holdings Group Co., Ltd. (銀谷控股集團有限公司) since January 2012, as dean of Zhongyi (Beijing) Vaccine and Health Institute (中義(北京)健康研究院) since July 2016, as general manager and executive director at Zhongyi (Taizhou) Pharmaceutical Technology Co., Ltd. (中義(泰州)醫藥科技有限公司) since February 2018 and as general manager and executive director at Mianzhu Yingu Rose Trading Co., Ltd. (綿竹銀谷玫瑰商貿有限公司) since November 2015.

Mr. Liu served as chief of Disease Control Division of the General Administration of Quality Supervision, Inspection and Quarantine (國家質量監督檢驗檢疫總局) from July 1989 to June 2003. From July 2003 to December 2011, he served as director of Scientific Affairs Department at Sanofi Pasteur, the vaccines division of the pharmaceutical company Sanofi S.A.

Mr. Liu obtained his bachelor's degree in medicine from Peking University Health Science Center (北京大學醫學部) in June 1989. He received his master's degree in health sciences from Curtin University in Australia in March 1998.

**Ms. Jiangfeng LI (李江峰)**, aged 42, has been serving as managing director of medical health investment department at Fortune Venture Capital Co., Ltd. (深圳市達晨財智創業投資管理有限公司) since March 2011. Ms. Li has been director of several companies, including Pharmapack Technologies Corporation (廣州珐瑪珈智能設備股份有限公司) since October 2011, Guangzhou Sunjava Medical Information Industry Co., Ltd. (廣州市三甲醫療信息產業有限公司) since June 2015, Guangdong Lanca Medical Device Technology Co., Ltd. (廣東朗呈醫療器械科技有限公司) since September 2015, Shanghai Akmpath Biotechnology Co., Ltd. (上海菲爾紹阿克曼生物科技有限公司) since August 2018, Shanghai OPM Biosciences Co., Ltd. (上海奧浦邁生物科技有限公司) since October 2018, Shanghai Akmpath Medical Laboratory Co., Ltd. (上海阿克曼醫學檢驗所有限公司) since October 2018. She has also been supervisor of Shenzhen Kairuikang Information Technology Co., Ltd. (深圳市凱瑞康信息技術有限公司) and Guangdong OptoMedic Technologies Inc. (廣東歐譜曼迪科技有限公司) since January 2016 and August 2016, respectively.

Ms. Li served as investment manager at Guangzhou Technology Venture Capital Co., Ltd. (廣州科技創業投資有限公司) from February 2004 to August 2007. She served as investment director at Guangzhou Hiway Capital Co., Ltd. (廣州海匯投資管理有限公司) from August 2007 to March 2011.

Ms. Li obtained her bachelor's degree in biochemistry and molecular biology from Nankai University (南開大學) in July 1999. She received her master's degree in biochemistry and molecular biology from Nankai University in July 2002.

The terms of office of Mr. Gui and Mr. Liu shall commence from the date of approval at the EGM until the expiry of the term of the first session of the Board. They shall be eligible for re-election upon the expiry of their terms of office. The Company will enter into a service contract with each of Mr. Gui and Mr. Liu upon approval at the EGM. Each of Mr. Gui and Mr. Liu will receive an annual director's fee of RMB300,000 (tax included) from the Company.

The term of office of Ms. Li shall commence from the date of approval at the EGM until the expiry of the term of the first session of the Board of Supervisors. She shall be eligible for re-election upon the expiry of her term of office. The Company will enter into a service contract with Ms. Li upon approval at the EGM. Ms. Li will not receive remuneration from the Company during her term of office.

Save as disclosed above, Mr. Gui, Mr. Liu and Ms. Li did not hold any directorships in any listed companies in the past three years prior to the date of this announcement, did not hold any positions in the Company or any of its subsidiaries, and did not have any relationship with any Directors, senior management or substantial or controlling shareholders of the Company. As at the date of this announcement, Mr. Gui, Mr. Liu and Ms. Li did not have any interest in the securities of the Company (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)). Mr. Gui, Mr. Liu and Ms. Li have not been subject to any penalty or punishment imposed by the China Securities Regulatory Commission or any other relevant authorities or stock exchanges.

Save as disclosed above, the Board is not aware of other information on the proposed appointment of Mr. Gui, Mr. Liu and Ms. Li which shall be disclosed pursuant to the requirements set out in Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters that need to be brought to the attention of the shareholders of the Company.

A Board meeting will be held upon conclusion of the EGM to nominate and appoint members of the Remuneration and Assessment Committee and the Nomination Committee. A meeting of the Board of Supervisors will be held upon conclusion of the EGM to elect the chairman of the Board of Supervisors. The Company will comply with the relevant requirements in relation to composition of the Board under the Listing Rules and make further announcement as appropriate.

On behalf of the Board of Directors  
**CanSino Biologics Inc.**  
**Xuefeng YU**  
*Chairman*

Hong Kong, November 14, 2019

*As at the date of this announcement, the Board of Directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU and Dr. Dongxu QIU as executive Directors, Mr. Qiang XU, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive Directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Dr. Luis BARRETO and Dr. Pierre Armand MORGON as independent non-executive Directors.*